Poseida Therapeutics Inc (NASDAQ: PSTX) kicked off on Tuesday, up 227.97% from the previous trading day, before settling in for the closing price of $2.86. Over the past 52 weeks, PSTX has traded in a range of $1.87-$4.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 53.46%. While this was happening, its average annual earnings per share was recorded 48.36%. With a float of $67.79 million, this company’s outstanding shares have now reached $95.64 million.
Let’s determine the extent of company efficiency that accounts for 330 employees. In terms of profitability, gross margin is 95.42%, operating margin of -41.43%, and the pretax margin is -40.25%.
Poseida Therapeutics Inc (PSTX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Poseida Therapeutics Inc is 30.45%, while institutional ownership is 52.99%. The most recent insider transaction that took place on Nov 26 ’24, was worth 343,200.
Poseida Therapeutics Inc (PSTX) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.27 earnings per share (EPS), higher than consensus estimate (set at -0.36) by 0.09. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 48.36% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.70% during the next five years compared to -12.83% drop over the previous five years of trading.
Poseida Therapeutics Inc (NASDAQ: PSTX) Trading Performance Indicators
Take a look at Poseida Therapeutics Inc’s (PSTX) current performance indicators. Last quarter, stock had a quick ratio of 3.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.06.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.63, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.69 in one year’s time.
Technical Analysis of Poseida Therapeutics Inc (PSTX)
Looking closely at Poseida Therapeutics Inc (NASDAQ: PSTX), its last 5-days average volume was 6.3 million, which is a jump from its year-to-date volume of 0.69 million. As of the previous 9 days, the stock’s Stochastic %D was 42.61%. Additionally, its Average True Range was 0.70.
During the past 100 days, Poseida Therapeutics Inc’s (PSTX) raw stochastic average was set at 99.58%, which indicates a significant increase from 99.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 496.65% in the past 14 days, which was higher than the 203.31% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.90, while its 200-day Moving Average is $2.98. However, in the short run, Poseida Therapeutics Inc’s stock first resistance to watch stands at $9.44. Second resistance stands at $9.51. The third major resistance level sits at $9.60. If the price goes on to break the first support level at $9.28, it is likely to go to the next support level at $9.19. Now, if the price goes above the second support level, the third support stands at $9.12.
Poseida Therapeutics Inc (NASDAQ: PSTX) Key Stats
The company with the Market Capitalisation of 914.22 million has total of 97,465K Shares Outstanding. Its annual sales at the moment are 64,700 K in contrast with the sum of -123,430 K annual income. Company’s last quarter sales were recorded 71,750 K and last quarter income was 20,240 K.
